
Revvity Inc (RVTY) Stock Forecast & Price Target
Revvity Inc (RVTY) Analyst Ratings
Bulls say
Revvity's stock outlook appears positive due to its robust growth trajectory, driven by strategic transitions in the market and an evolving product portfolio. The company benefits from a diversified mix of high-margin businesses, including its software segment, Signals, and its leading positions in life science reagents and immunodiagnostics, which have collectively positioned it for above-market growth in key areas such as autoimmune testing. Additionally, ongoing margin improvements and operational efficiencies indicate a higher profitability potential, enhancing Revvity's overall financial profile and market competitiveness.
Bears say
Revvity's stock outlook is negatively impacted by significant revenue declines in its China segment, particularly in Immunodiagnostics, which experienced a double-digit percentage drop in the second quarter of 2025 and is projected to contribute less than 5% of total revenue by 2026. Furthermore, broader economic conditions, including industry funding cuts, pose risks to customer demand, which could adversely affect Revvity's market share and overall financial performance. Additionally, potential macroeconomic changes such as product shortages, inflation, and labor challenges may disrupt the company's supply chain, further complicating its operational delivery and growth prospects.
This aggregate rating is based on analysts' research of Revvity Inc and is not a guaranteed prediction by Public.com or investment advice.
Revvity Inc (RVTY) Analyst Forecast & Price Prediction
Start investing in Revvity Inc (RVTY)
Order type
Buy in
Order amount
Est. shares
0 shares